EGLN3 and metastatic neoplasm: Given PHD3′s purported ability to negatively regulate the NFκB pathway [30], [35], and the widely reported involvement of NFκB in cell migration and metastasis [39], [40], future studies on PHD3 CpG island methylation in clinical samples of metastatic disease as opposed to primary tumors may yield more positive results.